🇺🇸 FDA

Intelligence · Clinical Pipeline

Phase I Pipeline Programs

First-in-human and early clinical safety studies in Phase I.

Programs
4,713

Quick answer

NovaPharmaNews tracks 4,713 phase i pharmaceutical pipeline programs from ClinicalTrials.gov. First-in-human and early clinical safety studies in Phase I.

Top sponsors

Page 68 of 99

  1. Peldesine

    Biocryst

    HIV Infections

    phase 1 small molecule completed

    1 trial

  2. Pembrolizumab

    Cardiff Oncology

    Anal Cancer Stage III A

    phase 1 small molecule active

    1 trial

  3. Pembrolizumab

    United Therapeutics Europe Ltd

    Cervix Cancer

    phase 1 other terminated

    1 trial

  4. Pembrolizumab

    United Therapeutics Europe Ltd

    Thoracic Tumours

    phase 1 small molecule completed

    1 trial

  5. Pembrolizumab

    Takeda

    Carcinoma, Non-Small-Cell Lung

    phase 1 small molecule completed

    1 trial

  6. Pembrolizumab plus autologous dendritic cell vaccine in patients with advanced mesothelioma who have failed prior therapies

    Istituto Gentili S.r.l.

    Mesothelioma

    phase 1 other active

    1 trial

  7. Pemetrexed

    The First People's Hospital of Lianyungang

    Leptomeningeal Metastases

    phase 1 small molecule completed

    1 trial

  8. Pemetrexed STADA 25 mg/ml Konzentrat zur Herstellung einer Infusionslösung, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Pemetrexed Fresenius Kabi 100 mg powder for concentrate for solution for infusion, Pemetrexed Fresenius Kabi 100 mg powder for concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, RMC-6236, Cisplatinum Accord, 1 mg/ml, koncentrat do sporządzania roztworu do infuzji., CARBOPLATIN-EBEWE, 10 MG/ML, KONCENTRAT DO SPORZĄDZANIA ROZTWORU DO

    Revolution Medicines

    Lung Cancer

    phase 1 small molecule active

    1 trial

  9. Pemetrexed Synthon 25 mg/ml, concentraat voor oplossing voor infusie, DARAXONRASIB (RMC-6236), Pemetrexed Fresenius Kabi 100 mg powder for concentrate for solution for infusion, Cisplatin Hikma 1 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Carboplatin Kabi 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, DARAXONRASIB (RMC-6236), Cisplatinum Accord, 1 mg/ml, koncentrat do sporządzania roztworu do infuzji., CISPLATIN-EBEWE, 1 MG/ML, KONCENTRAT DO SPORZĄDZANIA ROZTWORU DO INFUZJI, Pemetre

    Revolution Medicines

    Lung Cancer

    phase 1 small molecule active

    1 trial

  10. Peptides (N,R&C) formulated in Montanide ISA 720

    BRIGHT MINDS BIOSCIENCES INC.

    Malaria, Vivax

    phase 1 small molecule completed

    1 trial

  11. Perindopril

    BRIGHT MINDS BIOSCIENCES INC.

    Methamphetamine Dependence

    phase 1 small molecule completed

    1 trial

  12. Period 1: AT-527 550 mg

    Atea Pharmaceuticals

    Healthy Volunteer Study

    phase 1 small molecule completed

    1 trial

  13. Pevifoscorvir Sodium (ALG-000184)

    Aligos Therapeutics

    Chronic Hepatitis B Infection

    phase 1 small molecule active

    1 trial

  14. Pevifoscorvir Sodium (ALG-000184)

    Aligos Therapeutics

    Chronic Hepaititis B Infections

    phase 1 small molecule active

    1 trial

  15. Pevonedistat

    Takeda

    Myelofibroses

    phase 1 small molecule terminated

    1 trial

  16. Pevonedistat

    Takeda

    Refractory Acute Lymphoblastic Leukemia

    phase 1 small molecule completed

    1 trial

  17. Pevonedistat

    Takeda

    Acute Myelogenous Leukemia

    phase 1 small molecule completed

    1 trial

  18. Pevonedistat

    Takeda

    Advanced Solid Neoplasm

    phase 1 small molecule completed

    2 trials

  19. Pevonedistat

    Takeda

    Advanced Solid Tumors, Neoplasms, Advanced Solid

    phase 1 small molecule completed

    1 trial

  20. Pevonedistat 25 mg/m^2

    Takeda

    Leukemia, Myeloid, Acute

    phase 1 small molecule completed

    1 trial

  21. Pf-04937319

    Pfizer

    Healthy

    phase 1 small molecule completed

    1 trial

  22. Ph 1 Study of ORIC-944 in Patients with Metastatic Prostate Cancer.

    Topiloric/Uriadec

    Prostate cancer

    phase 1 other active

    1 trial

  23. Pharmaceutical-lipid aspirin (PL-ASA)

    Protalix BioTherapeutics

    Bioequivalence

    phase 1 small molecule completed

    1 trial

  24. Pharmacogenomics testing for clopidogrel responsiveness

    BRIGHT MINDS BIOSCIENCES INC.

    Stroke

    phase 1 other completed

    1 trial

  25. Pharmacokinetic comparison of efanesoctocog alfa vs other EHL-rFVIII products in participants with severe haemophilia A

    Swedish Orphan Biovitrum AB (publ)

    Haemophilia A

    phase 1 other active

    1 trial

  26. Pharmacokinetic study of colistimethate sodium

    Zaklady FarmaFarmaceutyczne Polpharma S.Aceutyczne Polpharma S.A.

    serious infections caused by selected aerobic gram-negative pathogens in patients with limited treatment options

    phase 1 other active

    1 trial

  27. Pharmacokinetic study of minocycline in patients with nontuberculous mycobacterial disease

    Disc Medicine

    Nontuberculous mycobacterial disease

    phase 1 other active

    1 trial

  28. Pharmacokinetic, Safety, Tolerability, and Immunogenicity Comparison of CKD-704 (risankizumab biosimilar), with EU-approved Skyrizi®, and US licensed Skyrizi® in Healthy Adult Participants

    Lacuna Pharma Pty Ltd

    Active psoriatic arthritis, Moderately to severely active Crohn’s disease, Moderate-to-severe plaque psoriasis, Moderately to severely active ulcerative colitis

    phase 1 other active

    1 trial

  29. Pharmacokinetics, pharmacodynamics, safety, and tolerability of an acetonic milk thistle extract, standardized to silymarin, in subjects with MASLD

    Topiloric/Uriadec

    chronic liver disease

    phase 1 other active

    1 trial

  30. Pharmacy-based methadone administration and dispensing

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid-use Disorder

    phase 1 small molecule completed

    1 trial

  31. Phase 0 trial of CBD in recurrent glioblastoma patients

    Disc Medicine

    Glioblastoma

    phase 1 other active

    1 trial

  32. Phase 1 First in Human Study to Explore AMG 355 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

    Amgen

    Dose Escalation: Non-small cell lung cancer (NSCLC), colorectal cancer (CRC), gastric cancer (GC), melanoma (MEL). Dose Confirmation: Lead Indication based on data from dose escalation. Dose Expansion: Tertiary Lymphoid Structure positive (TLS+) CRC, GC, and NSCLC.

    phase 1 other active

    1 trial

  33. Phase 1 First-in-Human Study of JNJ-95566692 in Participants with NHLs

    Janssen-Cilag International N.V.

    Non-Hodgkin Lymphoid Malignancies (NHLs)

    phase 1 other active

    1 trial

  34. Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cycles

    Tyra Biosciences

    Locally Advanced Cholangiocarcinoma

    phase 1 small molecule active

    1 trial

  35. Phase 1 Safety and Tolerability Study of ALN-F1202 in Healthy Adults.

    Lacuna Pharma Pty Ltd

    Healthy Volunteer

    phase 1 other active

    1 trial

  36. Phase 1 Safety and Tolerability Study of REGN9533 in Healthy Adults.

    Lacuna Pharma Pty Ltd

    Healthy Volunteers

    phase 1 other active

    1 trial

  37. Phase 1 Single Ascending Doses (SAD) of M5542 in Healthy Participants

    Merck Sharp and Dohme

    Healthy

    phase 1 other active

    1 trial

  38. Phase 1 Study of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer

    Amgen

    Metastatic Castration-Resistant Prostate Cancer (mCRPC)

    phase 1 other active

    1 trial

  39. Phase 1 Study of AZD9833 Alone or in Combination in Women with Advanced Breast Cancer

    AstraZeneca AB

    "Estrogen Receptor Positive HER2 Negative Advanced Breast Cancer"

    phase 1 other active

    1 trial

  40. Phase 1 Study of IMC-P115C in Advanced PRAME Positive Cancers

    Immunocore Ireland Limited

    Advanced PRAME Positive Cancers

    phase 1 other active

    1 trial

  41. Phase 1 Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancer

    Janssen-Cilag International N.V.

    Metastatic colorectal cancer and Gastric cancer

    phase 1 other active

    1 trial

  42. Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors

    Olema Pharmaceuticals

    Advanced or Metastatic Solid Tumors

    phase 1 other active

    1 trial

  43. Phase 1 Study of Oral LY3410738 in Patients with Advanced Hematologic Malignancies with IDH1 or IDH2 Mutations.

    Eli Lilly Co.

    Advanced Hematologic Malignancies

    phase 1 other active

    1 trial

  44. Phase 1 Study of PYX-106 in Solid Tumors

    Pyxis Oncology

    Solid Tumors

    phase 1 other active

    1 trial

  45. Phase 1 Study of PYX-201 in Solid Tumors

    Pyxis Oncology

    Advanced solid tumors

    phase 1 other active

    1 trial

  46. Phase 1 Study of Revumenib in Combination with Intensive Chemotherapy in Participants with AML Harboring Alterations in KMT2A/MLL, NPM1, or NUP98 Genes

    Syndax Pharmaceuticals

    Acute Myeloid Leukemias

    phase 1 other active

    1 trial

  47. Phase 1 dose-escalation trial of OMTX705, an anti-fibroblast activation protein antibody-drug conjugate, as single agent and in combination with anti-PD-1 or pazopanib in patients with advanced solid tumors

    Lacuna Pharma Pty Ltd

    Selected tumor indications that are known to express FAP (Fibroblast activation protein) either on tumor stroma CAFs (Cancer-associated fibroblasts) (carcinomas) or on tumor cells (leiomyosarcomas and other sarcomas).

    phase 1 other active

    1 trial

  48. Phase 1 study on SAR443122 bioavailability and food effect in healthy adults

    Sanofi-aventis Healthcare Pty Ltd

    Colitis ulcerative

    phase 1 other active

    1 trial

Frequently asked questions

How many Phase I pipeline programs are in the directory?

4,713 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.